GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Legend Biotech LEGN · USD

Health Care · US listing · 🇺🇸 United States

Compare

24.29

+3.80%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$1.03bn

FY2017FY2025

Net income

−$296.8m

FY2017FY2025

Free cash flow

−$168.0m

FY2017FY2025

Shareholders' equity

$1.00bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$1.03bn$627.2m$285.1m$117.0m$68.8m$75.0m$61.8m$49.1m$23.6m
Research and development$414.7m$413.5m$382.2m$335.6m$313.3m$232.2m$161.9m$60.6m$8.2m
Operating income−$136.5m−$303.2m−$439.5m−$455.6m−$406.3m−$313.3m−$132.5m−$1.5m$13.8m
Net income−$296.8m−$177.0m−$518.3m−$446.3m−$403.6m−$266.4m−$101.6m−$2.8m$9.4m
Diluted earnings per share-1.61-0.97-2.85-2.81-2.75-2.01-1.01-0.030.07

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$1.73bn$1.67bn$1.85bn$1.33bn$1.12bn$722.1m$287.7m$429.0m$238.7m
Cash and short-term investments$948.6m$1.12bn$1.31bn$1.03bn$882.4m$506.1m$158.9m$216.2m$2.1m
Total liabilities$731.6m$629.6m$597.2m$586.7m$353.5m$122.3m$410.6m$420.4m$226.5m
Debt$326.5m$350.6m$328.7m$284.5m$123.0m$3.7m$6.1m$4.3m$300,000
Shareholders' equity$1.00bn$1.04bn$1.25bn$744.3m$765.9m$597.8m−$122.9m$8.6m$12.2m
Shares outstanding185m183m182m159m147m132m100m100m132m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$100.5m−$144.0m−$393.3m−$201.3m−$198.5m−$223.0m−$83.1m$307.7m−$2.4m
Capital spending−$67.6m−$14.1m−$22.7m−$22.3m−$45.4m−$30.3m−$39.2m−$21.0m−$887,000
Free cash flow−$168.0m−$158.1m−$416.0m−$223.6m−$243.9m−$253.3m−$122.2m$286.7m−$3.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$387.5m$305.1m$306.4m$272.3m$255.1m$195.1m$186.5m$160.2m
Operating income$57.7m−$49.8m−$20.6m−$43.5m−$21.9m−$50.6m−$74.4m−$70.1m
Net income$33.2m−$54.3m−$30.8m−$39.7m−$125.4m−$100.9m$26.3m−$125.3m
Diluted earnings per share0.17-0.28-0.17-0.21-0.68-0.550.14-0.69
Cash from operations−$20.0m−$85.0m−$105.0m$28.0m−$13.0m−$103.0m−$82.0m−$75.0m
Capital spending−$20.0m−$25.0m−$20.0m−$5.0m−$9.0m−$2.0m−$2.0m−$2.0m
Free cash flow−$40.0m−$110.0m−$125.0m$23.0m−$22.0m−$105.0m−$84.0m−$77.0m
Total assets$1.75bn$1.60bn$1.73bn$1.71bn$1.69bn$1.62bn$1.67bn$1.74bn
Cash and short-term investments$964.6m$834.6m$948.6m$992.6m$967.6m$1.01bn$1.12bn$1.21bn
Debt$168.2m$277.2m$326.5m$322.2m$316.2m$311.1m$306.0m$301.0m
Shareholders' equity$1.23bn$967.7m$1.00bn$1.01bn$1.04bn$1.02bn$1.04bn$1.12bn

Financial ratios

Data as of 23 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-25.4%-21.8%-174.8%-371.7%-590.3%-410.8%
Net margin-28.8%-28.2%-181.8%-381.5%-586.4%-355.2%
Return on equity-29.6%-17.0%-41.4%-60.0%-52.7%-44.6%
Return on assets-17.1%-10.6%-28.0%-33.5%-36.1%-36.9%
Free cash flow yield-0.9%-3.8%-10.8%-6.0%-5.5%-7.7%
Revenue growth64.0%120.0%143.7%70.0%-8.2%21.4%
Earnings growth67.7%-65.8%16.1%10.6%51.5%162.2%
Current ratio1.96x4.62x6.92x3.69x4.14x5.14x
Debt to equity0.33x0.29x0.23x0.36x0.16x0.00x
Equity ratio57.8%62.3%67.7%55.9%68.4%82.8%
Interest coverage-12.21x-6.32x-22.87x-40.29x-451.44x-73.20x
R&D as a share of sales40.3%65.9%134.0%286.9%455.3%309.5%
Buybacks as a share of market value-1.0%-0.5%-14.4%-8.5%-10.8%-32.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue106.4%68.8%—
Operating income-33.1%-15.3%—
Net income-12.7%2.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-13.5-33.6-21.1-17.8-16.9-14.0
Price to sales3.99.538.467.999.349.7

Market value over time

30 Jun 2020 to 22 Oct 2026, in USD

$4.60bn$3.66bn

Share price return

Finished calendar years

202520242023202220212020
Return-37%-45%25%5%50%-16%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.